Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study
Objective To compare the 1-year retention rate of secukinumab in axial spondyloarthritis (axSpA) and its predisposing factors with regard to its time of initiation (eg, right after or remotely from its launch).Methods Study design: Retrospective multicentre French study of patients with axSpA. Study...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-02-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/10/1/e003942.full |
| _version_ | 1797222256074555392 |
|---|---|
| author | Maxime Dougados Pascal Claudepierre Philippe Goupille Alain Saraux Anne Tournadre Daniel Wendling Cédric Lukas Adeline Ryussen-Witrand Emilie Desfleurs Audrey Lardy-Cleaud |
| author_facet | Maxime Dougados Pascal Claudepierre Philippe Goupille Alain Saraux Anne Tournadre Daniel Wendling Cédric Lukas Adeline Ryussen-Witrand Emilie Desfleurs Audrey Lardy-Cleaud |
| author_sort | Maxime Dougados |
| collection | DOAJ |
| description | Objective To compare the 1-year retention rate of secukinumab in axial spondyloarthritis (axSpA) and its predisposing factors with regard to its time of initiation (eg, right after or remotely from its launch).Methods Study design: Retrospective multicentre French study of patients with axSpA. Study periods: Two cohorts were evaluated regarding the time of initiation of secukinumab: cohort 1 (C1)—between 16 August 2016 and 31 August 2018—and cohort 2 (C2)—between 1 September 2018 and 13 November 2020. Statistical analysis: The 1-year retention rate of secukinumab was estimated using the Kaplan-Meier method, and the log-rank test was used to compare the retention curves of the two cohorts. Preselected factors (eg, disease characterristics, line and time of secukinumab initiation) of secukinumab retention at 1 year were analysed by univariate and multivariate Cox model regression.Results In total, 906 patients in C1 and 758 in C2 from 50 centres were included in the analysis. The 1-year retention rate was better in C2 (64% (61%–68%)) vs C1 (59% (55%–62%)) (HR=1.19 (1.02–1.39); p=0.0297). In the multivariate analysis, the line of biologic therapy was the single predictive factor of the 1-year retention rate of secukinumab picked up in both cohorts, with a better retention rate when prescribed as first-line biologic therapy.Conclusion The better secukinumab retention rate remotely from its launch is explained by its use at an earlier stage of the disease, suggesting a change in the behaviour of prescribing physicians. Our results emphasise the relevance of iterative evaluations of routine care treatments. |
| first_indexed | 2024-03-07T19:11:33Z |
| format | Article |
| id | doaj.art-a760ea7964cf438ca2dc3456a1053520 |
| institution | Directory Open Access Journal |
| issn | 2056-5933 |
| language | English |
| last_indexed | 2024-04-24T13:18:26Z |
| publishDate | 2024-02-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj.art-a760ea7964cf438ca2dc3456a10535202024-04-04T16:55:09ZengBMJ Publishing GroupRMD Open2056-59332024-02-0110110.1136/rmdopen-2023-003942Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA studyMaxime Dougados0Pascal Claudepierre1Philippe Goupille2Alain Saraux3Anne Tournadre4Daniel Wendling5Cédric Lukas6Adeline Ryussen-Witrand7Emilie Desfleurs8Audrey Lardy-Cleaud9Hopital Cochin, Rheumatology, Université Paris Descartes Faculté de Médecine, Paris, FranceRheumatology, Hôpital Henri Mondor, Créteil, FranceRheumatology, CHU Tours, TOURS, FranceUniversité de Bretagne Occidentale (Univ Brest), Brest, FranceRheumatology, Clermont-Ferrand University Hospital, Rheumatology Department, UNH-UMR 1019, INRAe and University Clermont Auvergne, Clermont-Ferrand, FranceRheumatology, CHU J Minjoz, Besancon, FranceRheumatology, University Hospital Lapeyronie, Montpellier, FranceRheumatology, CHU Purpan, Toulouse, FranceNovartis Pharma France, Rueil Malmaison, FranceBiostatistics RCTs Clinical Research Organization, Lyon, FranceObjective To compare the 1-year retention rate of secukinumab in axial spondyloarthritis (axSpA) and its predisposing factors with regard to its time of initiation (eg, right after or remotely from its launch).Methods Study design: Retrospective multicentre French study of patients with axSpA. Study periods: Two cohorts were evaluated regarding the time of initiation of secukinumab: cohort 1 (C1)—between 16 August 2016 and 31 August 2018—and cohort 2 (C2)—between 1 September 2018 and 13 November 2020. Statistical analysis: The 1-year retention rate of secukinumab was estimated using the Kaplan-Meier method, and the log-rank test was used to compare the retention curves of the two cohorts. Preselected factors (eg, disease characterristics, line and time of secukinumab initiation) of secukinumab retention at 1 year were analysed by univariate and multivariate Cox model regression.Results In total, 906 patients in C1 and 758 in C2 from 50 centres were included in the analysis. The 1-year retention rate was better in C2 (64% (61%–68%)) vs C1 (59% (55%–62%)) (HR=1.19 (1.02–1.39); p=0.0297). In the multivariate analysis, the line of biologic therapy was the single predictive factor of the 1-year retention rate of secukinumab picked up in both cohorts, with a better retention rate when prescribed as first-line biologic therapy.Conclusion The better secukinumab retention rate remotely from its launch is explained by its use at an earlier stage of the disease, suggesting a change in the behaviour of prescribing physicians. Our results emphasise the relevance of iterative evaluations of routine care treatments.https://rmdopen.bmj.com/content/10/1/e003942.full |
| spellingShingle | Maxime Dougados Pascal Claudepierre Philippe Goupille Alain Saraux Anne Tournadre Daniel Wendling Cédric Lukas Adeline Ryussen-Witrand Emilie Desfleurs Audrey Lardy-Cleaud Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study RMD Open |
| title | Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study |
| title_full | Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study |
| title_fullStr | Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study |
| title_full_unstemmed | Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study |
| title_short | Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study |
| title_sort | impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis axspa data from the french multicentre retrospective forsya study |
| url | https://rmdopen.bmj.com/content/10/1/e003942.full |
| work_keys_str_mv | AT maximedougados impactofthetimeofinitiationandlineofbiologictherapyontheretentionrateofsecukinumabinaxialspondyloarthritisaxspadatafromthefrenchmulticentreretrospectiveforsyastudy AT pascalclaudepierre impactofthetimeofinitiationandlineofbiologictherapyontheretentionrateofsecukinumabinaxialspondyloarthritisaxspadatafromthefrenchmulticentreretrospectiveforsyastudy AT philippegoupille impactofthetimeofinitiationandlineofbiologictherapyontheretentionrateofsecukinumabinaxialspondyloarthritisaxspadatafromthefrenchmulticentreretrospectiveforsyastudy AT alainsaraux impactofthetimeofinitiationandlineofbiologictherapyontheretentionrateofsecukinumabinaxialspondyloarthritisaxspadatafromthefrenchmulticentreretrospectiveforsyastudy AT annetournadre impactofthetimeofinitiationandlineofbiologictherapyontheretentionrateofsecukinumabinaxialspondyloarthritisaxspadatafromthefrenchmulticentreretrospectiveforsyastudy AT danielwendling impactofthetimeofinitiationandlineofbiologictherapyontheretentionrateofsecukinumabinaxialspondyloarthritisaxspadatafromthefrenchmulticentreretrospectiveforsyastudy AT cedriclukas impactofthetimeofinitiationandlineofbiologictherapyontheretentionrateofsecukinumabinaxialspondyloarthritisaxspadatafromthefrenchmulticentreretrospectiveforsyastudy AT adelineryussenwitrand impactofthetimeofinitiationandlineofbiologictherapyontheretentionrateofsecukinumabinaxialspondyloarthritisaxspadatafromthefrenchmulticentreretrospectiveforsyastudy AT emiliedesfleurs impactofthetimeofinitiationandlineofbiologictherapyontheretentionrateofsecukinumabinaxialspondyloarthritisaxspadatafromthefrenchmulticentreretrospectiveforsyastudy AT audreylardycleaud impactofthetimeofinitiationandlineofbiologictherapyontheretentionrateofsecukinumabinaxialspondyloarthritisaxspadatafromthefrenchmulticentreretrospectiveforsyastudy |